Kiromic BioPharma (Kiromic BioPharma) Interest Expense : $-2.47 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kiromic BioPharma's interest expense for the three months ended in Mar. 2024 was $ -1.07 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.47 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kiromic BioPharma's Operating Income for the three months ended in Mar. 2024 was $ -5.11 Mil. Kiromic BioPharma's Interest Expense for the three months ended in Mar. 2024 was $ -1.07 Mil. Kiromic BioPharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kiromic BioPharma Interest Expense Historical Data

The historical data trend for Kiromic BioPharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Interest Expense Chart

Kiromic BioPharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.02

-0.01

-0.17

-1.85

Kiromic BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.44	-0.34	-0.43	-0.63	-1.07

Kiromic BioPharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.47 Mil.

Kiromic BioPharma (OTCPK:KRBP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kiromic BioPharma's Interest Expense for the three months ended in Mar. 2024 was $-1.07 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-5.11 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.75 Mil.

Kiromic BioPharma's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Kiromic BioPharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Kiromic BioPharma (Kiromic BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Fannin Street, Suite 140, Houston, TX, USA, 77054

Website

https://www.kiromic.com

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Executives

Brian Hungerford	officer: CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark	officer: Interim CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva	director, officer: Chairman, CEO, and President	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan	officer: Chief Technology Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez	officer: See Remarks	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider	director	ONE VISION DRIVE, NATICK MA 01760
Michael Nagel	director	C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani	director	C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck	officer: Chief Medical Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino	director, officer: CSIO	7707 FANNIN, SUITE 140, HOUSTON TX 77054